Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by educational grants from Bristol Myers Squibb, Janssen Biotech,Inc., administered by Janssen Scientific Affairs, LLC, Oncopeptides, and Sanofi Genzyme.

Uncovering New Multiple Myeloma Therapies and their Clinical Applications: Antibodies, CARs, BiTEs, and Beyond

Release Date: June 25, 2021
Expiration Date: September 25, 2021

Activity Overview

This online, on-demand virtual symposium brings together renowned experts in multiple myeloma to explain the mechanisms of action of newly approved and emerging therapies, as well as the key clinical data supporting the use of these new modalities. This education program also features an extended case-based session that will allow learners to consider how they might handle particular cases, integrate relevant evidence into real-world practice, and compare their patient care approaches with those of experts and peers.

This educational activity is an archive of the live virtual presentation held on June 8, 2021.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Bristol Myers Squibb, Janssen Biotech,Inc., administered by Janssen Scientific Affairs, LLC, Oncopeptides, and Sanofi Genzyme.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational program is directed toward medical oncologists and hematologist/oncologists who treat patients with multiple myeloma.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Explain the impact of disease-specific factors, risk assessment, and treatment history on therapy selection in R/R MM
  • Evaluate the safety and efficacy profiles of current and emerging therapies for patients with R/R MM
  • Implement proactive strategies to identify and minimize the negative impact of treatment-related toxicities in patents with R/R MM
  • Apply updated guidelines and evidence from landmark trials evaluating emerging therapeutic strategies for R/R MM to real-world clinical scenarios of patients with this malignancy

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.


Kenneth C. Anderson, MD
Kenneth C. Anderson, MD
Program Director, Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics
Institute Physician
Kraft Family Professor of Medicine, Harvard Medical School
Boston, MA

Disclosures: Consultant: Amgen, AstraZeneca, Bristol Myers Squibb, Janssen, Pfizer, Precision BioSciences; Stock/Shareholder: Scientific Founder: OncoPep/C4 Therapeutics.

Faith Davies, MD, MBBCh, MRCP, FRCPath
Faith Davies, MD, MBBCh, MRCP, FRCPath
Professor of Medicine
Director, Clinical Myeloma Program Perlmutter Cancer Center
NYU Langone Health
New York, NY

Disclosures: Grant/Research Support: Celgene; Consultant: Adaptive Biotechnologies, Bristol Myers Squibb, Celgene, GSK Janssen, Oncopeptides, Roche, Sanofi, Takeda.

Sagar Lonial, MD, FACP
Sagar Lonial, MD, FACP
Chair and Professor
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, GA

Disclosures: Consultant: AbbVie, Amgen, bluebird bio, Bristol Myers Squibb, Celgene, Janssen, Novartis, Sanofi, Takeda; Other: Board of Directors, TG Therapeutics.

Nina Shah, MD
Nina Shah, MD
Associate Professor, Department of Medicine
University of California San Francisco
San Francisco, CA

Disclosures: Grant Research Support: Bluebird Bio, Celgene/Bristol Myers Squibb, Janssen, Nektar Therapeutics, Poseida Therapeutics Sutro Biopharma, TeneoBio; Consultant: Amgen, Bristol Myers Squibb, CareDx, CSL Behring, GSK, Indapta Therapeutics, Karyopharm Therapeutics, Kite Pharma, Sanofi.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By